A Study of AK117 in Combination With Azacitidine in Patients With Myelodysplastic Syndromes

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2024
This is a Phase 2 randomized, double-blind, placebo-controlled, multicenter study evaluating the efficacy and safety of AK117 or placebo, combined with azacitidine in patients with newly diagnosed higher-risk myelodysplastic syndromes (HR-MDS).
Epistemonikos ID: 2c1aba72c02b6a8a5784b3e1d642513a23681b35
First added on: May 15, 2024